NeoGenomics logged a 1.6% change during today's morning session, and is now trading at a price of $13.74 per share. On average, analysts give it a target price of $21.18.
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. The small-cap company is based in the United States.
Make Sure to Consider the Following Before Buying NeoGenomics:
-
NeoGenomics has moved 14.0% over the last year.
-
NEO has a forward P/E ratio of -80.8 based on its EPS guidance of -0.17.
-
Over the last 4 years, earnings per share (EPS) have been growing at a compounded average rate of -16.7%.
-
The company has a price to earnings growth (PEG) ratio of -34.67.
-
Its Price to Book (P/B) ratio is 1.83
NeoGenomics Has Irregular and Negative Cash Flows
| Date Reported | Cash Flow from Operations ($ k) | Capital expenditures ($ k) | Free Cashflow ($ k) | YoY Growth (%) |
|---|---|---|---|---|
| 2022-12-31 | -65,993 | -30,891 | -96,884 | -6.62 |
| 2021-12-31 | -26,723 | -64,142 | -90,865 | -228.79 |
| 2020-12-31 | 1,460 | -29,096 | -27,636 | -927.43 |
| 2019-12-31 | 23,369 | -20,029 | 3,340 | n/a |
NeoGenomics has negative and highly variable free cash flows. They've averaged $-53.01 Million over the last 4 years, during which time they grew at a -16.3% compounded rate while displaying a coefficient of variability of 92.3%.
